Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26064980 | 0.88 | HTR2A (0.43) | HTR2AHTR2CHTR2B | |
| SCHEMBL26065005 | 0.83 | HTR2A (0.45) | HTR2AHTR2CHTR2B | |
| SCHEMBL26064994 | 0.76 | HTR2A (0.46) | HTR2AHTR2CHTR2B | |
| SCHEMBL26065404 | 0.74 | HTR2A (0.38) | HTR2AHTR2CHTR2B | |
| SCHEMBL26065014 | 0.71 | HTR2A (0.40) | HTR2AHTR2CHTR2B | |
| SCHEMBL26065019 | 0.71 | HTR2A (0.40) | HTR2AHTR2CHTR2B | |
| SCHEMBL26065011 | 0.71 | HTR2A (0.40) | HTR2AHTR2CHTR2B | |
| SCHEMBL26065010 | 0.71 | HTR2A (0.40) | HTR2AHTR2CHTR2B | |
| SCHEMBL26065362 | 0.71 | HTR2A (0.40) | HTR2AHTR2CHTR2B | |
| SCHEMBL26065397 | 0.70 | HTR1A (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265045-A1 | PHENALKYLAMINES AND METHODS OF TREATING MOOD DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265045-A1 | PHENALKYLAMINES AND METHODS OF TREATING MOOD DISORDERS | PNMT, HTR2C, HTR2A | SLC5A2 1138/4885HTR2A 3/4885HTR2C 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.